Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: Topographical evaluation of the IGF-1/IGFBP-2 and IGFBP-3 interface

Biochemistry

Volumn 43, Issue 36, 2004, Pages 11533-11545

  Robinson, Stephanie A ^a   Rosenzweig, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC EFFECTS; INSULIN LIKE GROWTH FACTOR BINDING PROTEINS (IGFBP); MONOBIOTINYLATED SPECIES; SOLID-PHASE-BINDING ESSAYS;

BIOCHEMISTRY; NITROGEN; PROTEINS;

INSULIN;

AVIDIN; BIOTIN; N HYDROXYSUCCINIMIDE BIOTIN; PEPSIN A; PEROXIDASE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; BIOAVAILABILITY; BIOSENSOR; BIOTINYLATION; CELL SURVIVAL; CONFERENCE PAPER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BIOTIN; BIOTINYLATION; CELL LINE, TRANSFORMED; CHO CELLS; CRICETINAE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUCCINIMIDES; SURFACE PLASMON RESONANCE;

EID: 4444337046     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi049082k     Document Type: Conference Paper

References (60)

1. Humbel, R. E. (1990) Insulin-like growth factors I and II, Eur. J. Biochem. 190, 445-462.
2. Baker, J., Liu, J., Robertson, E. J., and Efstratiadis, A. (1993) Role of the insulin-like growth factors in embryonic and postnatal growth, Cell 75, 73-82.
3. Daughaday, W. H., and Rotwein, P. (1989) Insulin-like growth factors I and II. Peptide, messanger ribonucleic acid and gene structures, serum, and tissue concentrations, Endocr. Rev. 10, 68-91.
4. D'Ercole, A. J. (1996) Insulin-like growth factors and their receptors in growth, Endocrinol. Metab. Clin. North Am. 25, 573-590.
5. Jones, J. I., and Clemmons, D. R. (1995) Insulin-like growth factors and their binding proteins: Biological actions, Endocr. Rev. 16, 3-34.
6. Imai, Y., Busby, W. H., Jr., Smith, C. E., Clarke, J. B., Garmong, A. J., Horwitz, G. D., Rees, C., and Clemmons, D. R. (1997) Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture, J. Clin. Invest. 100, 2596-2605.
7. Kodama, Y., Baxter, R. C., and Martin, J. L. (2002) Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line, Am. J. Respir. Cell Mol. Biol. 27, 336-344.
8. Figueroa, J. A., Sharma, J., Jackson, J. G., McDermott, M. J., Hilsenbeck, S. G., and Yee, D. (1993) Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells, J. Cell. Physiol. 157, 229-236.
9. Van den Berg, C. L., Cox, G. N., Stroh, C. A., Hilsenbeck, S. G., Weng, C. N., McDermott, M. J., Pratt, D., Osborne, C. K., Coronado-Heinsohn, E. B., and Yee, D. (1997) Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice, Eur. J. Cancer 33, 1108-1113.
10. Arteaga, C. L., Kitten, L. J., Coronado, E. B., Jacobs, S., Kull, F. C., Jr., Allred, D. C., and Osborne, C. K. (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice, J. Clin. Invest. 84, 1418-1423.
11. Sachdev, D., Li, S. L., Kartell, J. S., Fujita-Yamaguchi, Y., Miller, J. S., and Yee, D. (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I, Cancer Res. 63, 627-635.
12. Guler, H. P., Zapf, J., Schmid, C., and Froesch, E. R. (1989) Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates, Acta Endocrinol. 121, 753-758.
13. Hong, J., Zhang, G., Dong, F., and Rechler, M. M. (2002) Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells, J. Biol. Chem. 277, 10489-10497.
14. Rajah, R., Valentinis, B., and Cohen, P. (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism, J. Biol. Chem. 272, 12181-12188.
15. Cohen, P., Graves, H. C., Peehl, D. M., Kamarei, M., Giudice, L. C., and Rosenfeld, R. G. (1992) Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma, J. Clin. Endocrinol. Metab. 75, 1046-1053.
16. Collett-Solberg, P. F., and Cohen, P. (1996) The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action, Endocrinol. Metab. Clin. North Am. 25, 591-614.
17. Yamanaka, Y., Wilson, E. M., Rosenfeld, R. G., and Oh, Y. (1997) Inhibition of insulin receptor activation by insulin-like growth factor binding proteins, J. Biol. Chem. 272, 30729-30734.
18. Hwa, V., Oh, Y., and Rosenfeld, R. G. (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily, Endocr. Rev. 20, 761-787.
19. Smith, G. L., Doherty, A. P., Mitchell, H., Hanham, I. W., Christmas, T. J., and Epstein, R. J. (1999) Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer, Lancet 354, 2053-2054.
20. Ouban, A., Muraca, P., Yeatman, T., and Coppola, D. (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas, Hum. Pathol. 34, 803-808.
21. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study, Science 279, 563-566.
22. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet 351, 1393-1396.
23. Mauro, L., Salerno, M., Morelli, C., Boterberg, T., Bracke, M. E., and Surmacz, E. (2003) Role of the IGF-I receptor in the regulation of cell-cell adhesion: Implications in cancer development and progression, J. Cell. Physiol. 194, 108-116.
24. Cooke, R. M., Harvey, T. S., and Campbell, I. D. (1991) Solution structure of human insulin-like growth factor 1: A nuclear magnetic resonance and restrained molecular dynamics study, Biochemistry 30, 5484-5491.
25. Blundell, T. L., Bedarkar, S., Rinderknecht, E., and Humbel, R. E. (1978) Insulin-like growth factor: A model for tertiary structure accounting for immunoreactivity and receptor binding, Proc. Natl. Acad. Sci. U.S.A. 75, 180-184.
26. Szabo, L., Mottershead, D. G., Ballard, F. J., and Wallace, J. C. (1988) The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tri-peptide in IGF-1 for binding, Bochem. Biophys. Res. Commun. 151, 207-214.
27. Bayne, M. L., Applebaum, J., Chicchi, G. G., Hayes, N. S., Green, B. G., and Cascieri, M. A. (1988) Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor, J. Biol. Chem. 263, 6233-6239.
28. Cascieri, M. A., Chicchi, G. G., Applebaum, J., Green, B. G., Hayes, N. S., and Bayne, M. L. (1989) Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors, J. Biol. Chem. 264, 2199-2202.
29. Bagley, C. J., May, B. L., Szabo, L., McNamara, P. J., Ross, M., Francis, G. L., Ballard, F. J., and Wallace, J. C. (1989) A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide, Biochem. J. 259, 665-671.
30. Horney, M. J., Evangelista, C. A., and Rosenzweig, S. A. (2001) Synthesis and characterization of insulin-like growth factor (IGF)-1 photoprobes selective for the IGF-binding proteins (IGFBPS). Photoaffmity labeling of the IGF-binding domain on IGFBP-2, J. Biol. Chem. 276, 2880-2889.
31. Cascieri, M. A., Chicchi, G. G., Applebaum, J., Hayes, N. S., Green, B. G., and Bayne, M. L. (1988) Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor, Biochemistry 27, 3229-3233.
32. Maly, P., and Luthi, C. (1988) The binding sites of insulin-like growth factor I (IGF-I) to type I IGF receptor and to a monoclonal antibody. Mapping by chemical modification of tyrosine residues, J. Biol. Chem. 263, 7068-7072.
33. Firth, S. M., Ganeshprasad, U., and Baxter, R. C. (1998) Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3, J. Biol. Chem. 273, 2631-2638.
34. Zeslawski, W., Beisel, H. G., Kamionka, M., Kalus, W., Engh, R. A., Huber, R., Lang, K., and Holak, T. A. (2001) The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5, EMBO J. 20, 3638-3644.
35. Kalus, W., Zweckstetter, M., Renner, C., Sanchez, Y., Georgescu, J., Grol, M., Demuth, D., Schumacher, R., Dony, C., Lang, K., and Holak, T. A. (1998) Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): Implications for IGF and IGF-I receptor interactions, EMBO J. 17, 6558-6572.
36. Imai, Y., Moralez, A., Andag, U., Clarke, J. B., Busby, W. H., Jr., and Clemmons, D. R. (2000) Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions, J. Biol. Chem. 275, 18188-18194.
37. Brinkman, A., Kortleve, D. J., Zwarthoff, E. C., and Drop, S. L. (1991) Mutations in the C-terminal part of insulin-like growth factor (IGF)-binding protein-1 result in dimer formation and loss of IGF binding capacity, Mol. Endocrinol. 5, 987-994.
38. Forbes, B. E., Turner, D., Hodge, S. J., McNeil, K. A., Forsberg, G., and Wallace, J. C. (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain, J. Biol. Chem. 273, 4647-4652.
39. Ho, P. J., and Baxter, R. C. (1997) Characterization of truncated insulin-like growth factor-binding protein-2 in human milk, Endocrinology 138, 3811-3818.
40. Carrick, F. E., Forbes, B. E., and Wallace, J. C. (2001) BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains, J. Biol. Chem. 276, 27120-27128.
41. Payet, L. D., Wang, X. H., Baxter, R. C., and Firth, S. M. (2003) Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions, Endocrinology 144, 2797-2806.
42. Shand, J. H., Beattie, J., Song, H., Phillips, K., Kelly, S. M., Flint, D. J., and Allan, G. J. (2003) Specific amino acid substitutions determine the differential contribution of the N- and C-terminal domains of insulin-like growth factor (IGF)-binding protein-5 in binding IGF-I, J. Biol. Chem. 278, 17859-17866.
43. Urlaub, G., Kas, E., Carothers, A. M., and Chasin, L. A. (1983) Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells, Cell 33, 405-412.
44. Han, J. C., and Han, G. Y. (1994) A procedure for quantitative determination of tris(2-carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol, Anal. Biochem. 220, 5-10.
45. Honegger, A., and Humbel, R. E. (1986) Insulin-like growth factors I and II in fetal and adult bovine serum. Purification, primary structures, and immunological cross-reactivities, J. Biol. Chem. 261, 569-575.
46. Forsberg, G., Palm, G., Ekebacke, A., Josephson, S., and Hartmanis, M. (1990) Separation and characterization of modified variants of recombinant human insulin-like growth factor I derived from a fusion protein secreted from Escherichia coli, Biochem. J. 271, 357-363.
47. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227, 680-685.
48. Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S., and Binoux, M. (1986) Analysis of serum insulin-like growth factor binding proteins using western blotting: Use of the method for titration of the binding proteins and competitive binding studies, Anal. Biochem. 154, 138-143.
49. Horney, M. J., Shirley, D. W., Kurtz, D. T., and Rosenzweig, S. A. (1998) Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I, Am. J. Physiol. 274, F1045-F1053.
50. Yip, C. C., Hsu, H., Olefsky, J. M., and Seely, L. (1993) Preparation of N epsilon B28-monoazidobenzoyl insulin-like growth factor I and photoaffinity labeling of insulin-like growth factor I receptor, Peptides 14, 325-330.
51. Slomiany, M. G., and Rosenzweig, S. A. (2004) Induced VEGF and IGFBP-3 sretion correlates with increased HIF-1-a nuclear translocation in the retinal pigment epithelial cell line D407, Ophthalmol. Vis. Sci. in press.
52. Brzozowski, A. M., Dodson, E. J., Dodson, G. G., Murshudov, G. N., Verma, C., Turkenburg, J. P., de Bree, F. M., and Dauter, Z. (2002) Structural origins of the functional divergence of human insulin-like growth factor-I and insulin, Biochemistry 41, 9389-9397.
53. Schaffer, M. L., Deshayes, K., Nakamura, G., Sidhu, S., and Skelton, N. J. (2003) Complex with a phage display-derived peptide provides insight into the function of insulin-like growth factor I, Biochemistry 42, 9324-9334.
54. Brinkman, A., Kortleve, D. J., Schuller, A. G., Zwarthoff, E. C., and Drop, S. L. (1991) Site-directed mutagenesis of the N-terminal region of IGF binding protein 1; analysis of IGF binding capability, FEBS Lett. 291, 264-268.
55. Grulich-Henn, J., Spiess, S., Heinrich, U., Schonberg, D., and Bettendorf, M. (1998) Ligand blot analysis of insulin-like growth factor-binding proteins using biotinylated insulin-like growth factor-I, Horm. Res. 49, 1-7.
56. Fowlkes, J. L., and Serra, D. (1996) A rapid, non-radioactive method for the detection of insulin-like growth factor binding proteins by Western ligand blotting, Endocrinology 137, 5751-5754.
57. Op De Beeck, L., Verlooy, J. E., Van Buul-Offers, S. C., and Du Caju, M. V. (1997) Detection of serum insulin-like growth factor binding proteins on western ligand blots by biotinylated IGF and enhanced chemiluminescence, J. Endocrinol. 154, R1-R5.
58. Pepinsky, R. B., Rayhorn, P., Day, E. S., Dergay, A., Williams, K. P., Galdes, A., Taylor, F. R., Boriack-Sjodin, P. A., and Garber, E. A. (2000) Mapping sonic hedgehog-receptor interactions by steric interference, J. Biol. Chem. 275, 10995-11001.
59. Toedt, G. H., Krishnan, R., and Friedhoff, P. (2003) Site-specific protein modification to identify the MutL interface of MutH, Nucleic Acids Res. 31, 819-825.
60. Song, J., Midson, C., Blachly-Dyson, E., Forte, M., and Colombini, M. (1998) The topology of VDAC as probed by biotin modification, J. Biol. Chem. 273, 24406-24413.